Myriad Genetics Stock Investor Sentiment
| MYGN Stock | USD 16.27 0.01 0.06% |
About 61% of Myriad Genetics' investor base is looking to short. The analysis of the overall investor sentiment regarding Myriad Genetics suggests that many traders are alarmed. Myriad Genetics' investing sentiment overview a quick insight into current market opportunities from investing in Myriad Genetics. Many technical investors use Myriad Genetics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
39
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Myriad Genetics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Myriad Genetics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Myriad Historical Sentiment
Although Myriad Genetics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Myriad, such as negative comments on social media and news outlets, may cause fear in the market and push Myriad Genetics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Myriad.
Myriad |
Myriad Genetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Myriad Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Myriad Genetics Historical Investor Sentiment
Investor biases related to Myriad Genetics' public news can be used to forecast risks associated with an investment in Myriad. The trend in average sentiment can be used to explain how an investor holding Myriad can time the market purely based on public headlines and social activities around Myriad Genetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Myriad Genetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Myriad Genetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Myriad Genetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Myriad Genetics.
Far too much social signal, news, headlines, and media speculation about Myriad Genetics that are available to investors today. That information is available publicly through Myriad media outlets and privately through word of mouth or via Myriad internal channels. However, regardless of the origin, that massive amount of Myriad data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Myriad Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Myriad Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Myriad Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Myriad Genetics alpha.
Myriad Genetics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 964 shares by Natalie Munk of Myriad Genetics at 27.64 subject to Rule 16b-3 | 09/20/2024 |
2 | Disposition of 2515 shares by Kevin Haas of Myriad Genetics at 24.37 subject to Rule 16b-3 | 10/09/2024 |
3 | Disposition of 2231 shares by Ancona Margaret of Myriad Genetics at 22.72 subject to Rule 16b-3 | 10/22/2024 |
4 | Myriad Genetics Earnings Expected to Grow Should You Buy | 10/28/2024 |
5 | Myriad Genetics Q3 Earnings and Revenues Surpass Estimates | 11/07/2024 |
6 | MYGN ALERT - Levi Korsinsky Has Commenced an Investigation on Behalf of Myriad Genetics, Inc. Shareholders Who Lost Money | 11/11/2024 |
7 | Myriad Genetics, Inc. Investors with Losses are Urged to Contact Levi Korsinsky to Discuss Their Rights | 11/12/2024 |
8 | Myriad Genetics Sets New 52-Week Low Should You Sell | 11/13/2024 |
9 | MYGN INVESTOR ALERT Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm | 11/14/2024 |
10 | Myriad Genetics Upgraded at StockNews.com | 11/15/2024 |
11 | Arvinas reports delay in breast cancer trial results | 11/19/2024 |
12 | Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illuminas Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2 | 11/20/2024 |
13 | MYGN Stock Up on Integration of HRD Platform Into Illuminas TSO 500 v2 | 11/25/2024 |
Check out Myriad Genetics Hype Analysis, Myriad Genetics Correlation and Myriad Genetics Performance. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.